title: Specialized proresolving mediator targets for RvE1 and RvD1 in peripheral blood and mechanisms of resolution.
abstract: Inflammation when unchecked is associated with many prevalent disorders such as the classic inflammatory diseases arthritis and periodontal disease, as well as the more recent additions that include diabetes and cardiovascular maladies. Hence mechanisms to curtail the inflammatory response and promote catabasis are of immense interest. In recent years, evidence has prompted a paradigm shift whereby the resolution of acute inflammation is a biochemically active process regulated in part by endogenous PUFA (polyunsaturated fatty acid)-derived autacoids. Among these are a novel genus of SPMs (specialized proresolving mediators) that comprise novel families of mediators including lipoxins, resolvins, protectins and maresins. SPMs have distinct structures and act via specific G-protein seven transmembrane receptors that signal intracellular events on selective cellular targets activating proresolving programmes while countering pro-inflammatory signals. An appreciation of these endogenous pathways and mediators that control timely resolution opened a new terrain for therapeutic approaches targeted at stimulating resolution of local inflammation. In the present review, we provide an overview of the biosynthesis and actions of resolvin E1, underscoring its protective role in vascular systems and regulating platelet responses. We also give an overview of newly described resolution circuitry whereby resolvins govern miRNAs (microRNAs), and transcription factors that counter-regulate pro-inflammatory chemokines, cytokines and lipid mediators.
authors.affiliation: Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Harvard Institutes of Medicine and Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Gabrielle
authors.initials: G
authors.lastname: Fredman
authors.forename: Charles N
authors.initials: CN
authors.lastname: Serhan
mesh_terms: D000818:Animals; D012898:Autacoids / Q000502:physiology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D004281:Docosahexaenoic Acids / Q000502:physiology*; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000502:physiology; D006706:Homeostasis / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D018836:Inflammation Mediators / Q000494:pharmacology* / Q000502:physiology; D044045:Lipoxins / Q000502:physiology; D008264:Macrophages / Q000187:drug effects / Q000502:physiology; D051379:Mice; D035683:MicroRNAs / Q000378:metabolism; D051381:Rats
chemical_list: D012898:Autacoids; D018836:Inflammation Mediators; D044045:Lipoxins; D035683:MicroRNAs; C518399:resolvin D1; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid; C499823:5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid